Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Can-Fite BioPharma ( (CANF) ) is now available.
On February 5, 2026, Can-Fite BioPharma reported that a patient with advanced decompensated liver cirrhosis treated with its investigational drug Namodenoson under a compassionate use program subsequently underwent a successful liver transplant. According to the company, Namodenoson helped clinically stabilize the patient long enough to remain eligible for transplant until a suitable donor organ became available, suggesting the drug may have potential as a supportive “bridge to transplant” therapy in severe liver failure, a field where donor shortages and limited treatment options lead to high mortality. Experts cited in the release emphasized that the single-patient outcome must be interpreted cautiously but viewed it as an encouraging signal supporting ongoing clinical development of Namodenoson in advanced liver diseases, against the backdrop of a growing global cirrhosis burden and an expanding liver cirrhosis treatment market.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing proprietary small-molecule drugs targeting cancer, liver and inflammatory diseases, aiming at multi-billion-dollar markets. Its lead candidate Piclidenoson is in Phase III development for psoriasis, while its liver drug Namodenoson is in Phase III for hepatocellular carcinoma, Phase IIb for MASH, and Phase IIa for pancreatic cancer, with orphan drug status in the U.S. and Europe and Fast Track designation from the U.S. FDA for second-line HCC; a third candidate, CF602, is in development for erectile dysfunction, and the company reports an extensive safety database across more than 1,600 patients.
Average Trading Volume: 519,424
Technical Sentiment Signal: Sell
Current Market Cap: $5.56M
Find detailed analytics on CANF stock on TipRanks’ Stock Analysis page.